Abstract
Antibodies targeting amyloid-β aggregates slow decline in Alzheimer's disease.
MeSH terms
-
Alzheimer Disease* / therapy
-
Amyloid beta-Peptides* / immunology
-
Antibodies, Monoclonal, Humanized* / therapeutic use
-
Clinical Trials as Topic
-
Humans
-
Immunotherapy
Substances
-
Amyloid beta-Peptides
-
aducanumab
-
lecanemab
-
donanemab
-
Antibodies, Monoclonal, Humanized